Shanghai Tellgen Life Science

What Shanghai Tellgen Life Science does

Shanghai Tellgen Life Science Co., Ltd. (上海透景生命科技股份有限公司) is a Shanghai-based in vitro diagnostics (IVD) manufacturer founded in 2003 and listed on the Shenzhen Stock Exchange ChiNext board (ticker 300642) since 2017. The company operates from Shanghai Zhangjiang High-Tech Park in Pudong and employs between 1,001 and 5,000 people. Tellgen serves clinical laboratories and hospitals across China, providing diagnostic solutions for tumor monitoring, autoimmune diseases, cardiovascular disease, infectious pathogens, and reproductive health screening.

The company operates four proprietary technology platforms: flow cytometry fluorescence (流式荧光), chemiluminescence immunoassay (化学发光), multiplex fluorescent PCR, and liquid chromatography-tandem mass spectrometry (LC-MS/MS). Its flagship instrument, the TESMI F4000, achieves throughput of 4,000 tests per hour, a 20x speed improvement over traditional chemiluminescence methods limited to approximately 200 tests per hour. Tellgen's reagent menu includes 19 tumor markers on the flow platform, 23 tumor markers on the chemiluminescence platform, autoimmune antibody panels (16-item autoantibody profile, anti-CCP, vasculitis panel, antiphospholipid antibodies, autoimmune liver disease markers), TORCH screening, HPV genotyping (27-type, 5+9, 2+12 assays), molecular oncology tests (EGFR, KRAS, BRAF mutations, SHOX2/RASSF1A lung cancer methylation, SEPT9 colorectal methylation), thyroid function, cardiovascular markers (hs-cTnI, BNP, NT-proBNP, H-FABP), and 43 clinical biochemistry indicators. The company holds nearly 300 medical device registration certificates from the NMPA, including the only CFDA-approved multi-platform tumor marker quality control product covering 17 markers.

Tellgen's business model is sales-led, combining a direct sales force with a nationwide dealer and agent network organized around provincial exclusive distributors, each required to meet a minimum 8 million yuan annual sales threshold. Revenue is generated primarily through one-time sales of IVD reagents and instruments to clinical laboratories, hospitals, and medical institutions. The company has established integration partnerships with Hitachi Diagnostics (core strategic partner for the first domestic compatible automation pipeline in China), Abbott Laboratories (ARCHITECT i2000sr reagent compatibility), and Roche Diagnostics (Cobas e411 quality control validation). Financial data indicates significant revenue and earnings deterioration from 2021 through 2025, with reported revenue declining approximately 50% over the period alongside sharp EBITDA and net income compression.

Name

Shanghai Tellgen Life Science

Legal name

上海透景生命科技股份有限公司

Website

https://tellgen.com

Company type

Public

Founded year

2003

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Shanghai Tellgen Life Science is a Chinese IVD manufacturer operating flow fluorescence, chemiluminescence, multiplex PCR, and LC-MS/MS diagnostic platforms. It serves clinical laboratories and hospitals across China with nearly 300 NMPA-registered products spanning tumor markers, autoimmune, infectious disease, and reproductive health.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)

akta.pro secondary industries

Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing) (HLAAALAH), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• In vitro diagnostics
• Clinical diagnostic reagents
• Immunoassay instruments
• Tumor marker testing
• Flow cytometry reagents

Headquarters

HQ city

Pudong

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

1. IVD Reagent Sales: Sales of in vitro diagnostic reagents across multiple technology platforms including flow cytometry, chemiluminescence, molecular diagnostics and clinical biochemistry. Revenue generated from clinical laboratories, hospitals, and medical institutions through direct sales and distributor networks.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Shanghai Tellgen Life Science manufactures and sells high-end in vitro diagnostic (IVD) products, including flow cytometry fluorescence and chemiluminescence immunoassay analyzers, automated laboratory assembly lines, multiplex fluorescence PCR instruments, and a broad reagent menu spanning tumor markers, autoimmune antibodies, infectious disease (TORCH, HPV), cardiovascular panels, thyroid function, reproductive health, and methylation-based cancer screening. Products are sold to clinical laboratories and hospitals, and the company maintains compatibility with international platforms such as Abbott ARCHITECT, Roche Cobas, and Hitachi automation systems.

Product overview

Shanghai Tellgen Life Science is an in vitro diagnostics (IVD) company specializing in development, manufacturing, and sales of high-end diagnostic products. The company operates four main technology platforms: flow fluorescence (流式荧光), chemiluminescence (化学发光), multiplex fluorescence PCR (多重荧光PCR), and liquid chromatography-tandem mass spectrometry (液相色谱串联质谱). Product portfolio includes detection instruments (TESMI F4000, Luminex-200, TESMI i50/i200, SLAN series), automated assembly lines (快线精灵T9), and comprehensive reagent menus covering tumor markers (19 flow + 23 CLIA markers), autoimmune antibodies, TORCH screening, HPV genotyping, molecular diagnostics (EGFR, KRAS, BRAF mutations), methylation testing, thyroid function, cardiovascular markers, and clinical biochemistry (43 indicators). The company has accumulated nearly 300 medical device registration certificates, serving clinical applications in tumor monitoring, autoimmune diseases, cardiovascular diseases, infectious pathogens, and reproductive health.

Differentiator

Problem solved

Functional benefit

Products and services

• TESMI F4000 Fully automated high-throughput flow fluorescence luminescence immunoassay analyzer achieving 4,000 tests/hour, approximately 20 times faster than traditional chemiluminescence methods. Sold to high-volume hospital and independent clinical laboratories for multiplex immunoassay testing.
• Luminex-200 Multiplexed flow cytometry detection platform using coded microsphere technology for simultaneous quantification of multiple biomarkers in a single reaction. Targeted at clinical laboratories needing flexible multiplex analyte panels.
• TESMI i50 (发光小精灵) Compact automated chemiluminescence immunoassay analyzer for distributed testing scenarios with a small laboratory footprint. Sold to medium- and small-volume clinical laboratories.
• TESMI i200 (发光大精灵) Automated chemiluminescence immunoassay analyzer featuring non-clogging flow-cell technology intended for continuous, high-uptime clinical laboratory operation.
• SLAN-96S/48P Real-time fluorescence quantitative PCR instrument for clinical molecular diagnostics, providing efficient and rapid quantitative detection. Used with Tellgen HPV genotyping, EGFR/KRAS/BRAF mutation, and methylation reagent kits.
• Quick Line Spirit T9 (快线精灵T9) Third-generation fully automated total-laboratory-automation assembly line with high integration and intelligent high-speed processing. Sold as a complete workflow solution for high-volume hospital laboratories.
• Tellgen Immuno Twin-Island (透景免疫双子岛) Integrated dual-immunoassay workstation combining flow fluorescence and chemiluminescence detection on a single platform. Sold to clinical laboratories seeking both technologies from one consolidated footprint.
• Multi-Tumor Marker Quality Control Product (多肿瘤标志物质控品) Third-party multi-tumor marker quality control product covering 17 tumor markers across multiple platforms — described as the only CFDA-approved multi-platform value-assigned QC product in China. Used by clinical laboratories for cross-platform QC validation.
• ToRCH Prenatal Screening Reagent Kit 10-analyte TORCH screening kit with IgG/IgM detection for Toxoplasma, Rubella, CMV, HSV-I and HSV-II delivering a 5-fold speed improvement over conventional methods. Sold to prenatal-screening laboratories.
• Y Chromosome Microdeletion Detection Kit (Y6) Y chromosome microdeletion kit for male infertility assessment, compliant with EAA/EMQN guidelines with 6 STS sites per detection region. Sold to reproductive health and andrology laboratories.
• HPV 27 Nucleic Acid Genotyping Kit 27-type HPV genotyping assay detecting 17 high-risk and 10 low-risk HPV types in a single reaction with digital high-throughput results. Sold to cervical cancer screening programs.
• High-Risk HPV 5+9 Typing Kit High-risk HPV 5+9 typing kit (HPV 16/18/58/52/33 + 9 additional types) designed for Chinese HPV epidemiology. Sold to cervical cancer screening laboratories.
• High-Risk HPV 2+12 Typing Kit High-risk HPV 2+12 typing kit targeting HPV 16/18 plus 12 additional types, consistent with imported product standards. Sold to cervical cancer screening laboratories.
• Human EGFR Gene Mutation Detection Kit EGFR mutation detection kit covering exons 18–21, identifying 20 somatic mutations to guide EGFR-TKI targeted therapy decisions in lung cancer. Sold to molecular oncology laboratories.
• Lung Cancer Methylation Detection Kit (SHOX2 RASSF1A) Lung cancer methylation kit targeting SHOX2 and RASSF1A gene methylation to assist early lung cancer diagnosis. Sold to oncology and screening laboratories.
• Colorectal Cancer Methylation Detection Kit (SEPT9) SEPT9 methylation blood-based assay for non-invasive colorectal cancer screening with simple sample collection. Sold to screening and gastroenterology laboratories.
• Cardiovascular Disease Integrated Solution (心血管疾病整体解决方案) Integrated cardiovascular disease testing solution covering chest-pain differential diagnosis (hs-cTnI, CK-MB, MYO, H-FABP, BNP, NT-proBNP, sST2, D-Dimer) and heart-failure management panels. Sold to cardiology and emergency laboratories.
• Thyroid Function Quantitative Detection Kit (甲功) Thyroid function panel covering TSH, FT3, FT4, TT3, TT4, TPOAb, TgAb and Tg (8 markers) with total CV under 5% and third-generation TSH sensitivity. Sold to endocrinology and routine clinical laboratories.
• Autoimmune Antibody Detection Reagents Autoimmune antibody panel covering 16-item autoantibody profile, anti-CCP, vasculitis panel, antiphospholipid antibodies and autoimmune liver disease markers. Sold to rheumatology and immunology laboratories.
• Clinical Biochemistry Reagents Clinical biochemistry reagents covering liver function, kidney function, blood lipids, cardiac markers, glucose metabolism and pancreatic markers with 43 biochemical indicators. Sold to routine clinical laboratories.

Quantifiable outcome

• Detection speed up to 4000 tests/hour - 20x faster than traditional chemiluminescence (200 tests/hour)
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

Feature4 records

Partnerships

Three partnerships are on record, tiered core and supporting.

• Hitachi Diagnostics (日立诊断)coreTechnology or IntegrationStrategic partnership to launch Hitachi-Tellgen compatible automation pipeline, the first domestic compatible pipeline in China. Integrates Tellgen's diagnostic reagents with Hitachi's automation systems to provide comprehensive laboratory automation solutions.
• Abbott LaboratoriessupportingTechnology or IntegrationTellgen reagents are compatible with Abbott ARCHITECT i2000sr automated immunoassay system. Provides customers flexibility to use Tellgen products on Abbott platforms.
• Roche DiagnosticssupportingTechnology or IntegrationQuality control products validated for use with Roche Cobas e411 electrochemiluminescence immunoassay system, enabling multi-system quality control solutions.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Mindray Medical: Largest Chinese IVD and medical device incumbent; competes with Tellgen across chemiluminescence, hematology, and clinical chemistry, but at significantly larger scale and with a broader multi-modality portfolio.
• Siemens Healthineers: Global IVD incumbent with the Atellica/ADVIA Centaur immunoassay platforms that compete for the same Chinese hospital-laboratory test volume that Tellgen's TESMI and flow cytometry products address.
• Abbott Diagnostics: Global IVD incumbent whose ARCHITECT i2000sr runs Tellgen-compatible tumor-marker reagents while also directly competing with Tellgen's CLIA reagent portfolio for share of Chinese hospital immunoassay menus.
• Beckman Coulter (Danaher): Global immunoassay and clinical chemistry incumbent whose Access/DxI platforms overlap with Tellgen's reagent menu and compete in Chinese tertiary hospital laboratories for tumor marker and hormone testing share.
• Roche Diagnostics: Global immunoassay incumbent whose Cobas e411 platform integrates with Tellgen's QC products and competes with Tellgen's CLIA reagents in the same hospital laboratories, especially in tumor marker and infectious disease testing.

Direct peers

• BGI Genomics: Chinese molecular diagnostics and IVD player competing with Tellgen's PCR-based HPV genotyping, EGFR/KRAS/BRAF mutation, and SEPT9/SHOX2 methylation assay portfolio in oncology and reproductive health screening.
• Shenzhen New Industries Biomedical Engineering (Snibe): Chinese chemiluminescence immunoassay specialist with a large installed base of MAGLUMI analyzers — directly competes with Tellgen's TESMI CLIA instruments and tumor-marker reagent menu in mid- and high-volume hospital labs.
• Da An Gene (DaAn Genomics): Chinese molecular diagnostics company whose HPV, EGFR, and infectious-disease PCR kits compete head-to-head with Tellgen's molecular diagnostics reagent portfolio in Chinese hospital and CDC channels.
• Maccura Biotechnology: Chinese IVD company with chemiluminescence, clinical chemistry, and molecular diagnostic products, directly overlapping Tellgen's clinical biochemistry, immunoassay, and PCR-based HPV/EGFR reagent lines.
• Autobio Diagnostics: Leading Chinese IVD manufacturer with a chemiluminescence immunoassay platform and broad tumor-marker, infectious-disease, and hormone menus — directly overlaps Tellgen's core immunoassay reagent business and competes for the same hospital laboratory customers in China.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/shanghai-tellgen-life-science-co-ltd-

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shanghai Tellgen Life Science